Japan · Delayed Price · Currency is JPY Ribomic Company Description
Ribomic Inc. engages in the discovery and development of pharmaceutical compounds using RNA aptamers in Japan and Europe.
The company develops RBM-007, which is in Phase III clinical trial for the treatment of achondroplasia; Phase II clinical trial for the treatment of wet age-related macular degeneration; and pre-clinical trial for the treatment of diabetic macular edema.
It is also involved in the development of drugs in pre-clinical trial stage, including RBM-006 for the treatment of retinal disease, proliferative, vitreoretinopathy, glaucoma, and diabetic retinopathy; RBM-011 for the treatment of pulmonary arterial hypertension; RBM-003 for the treatment of heart failure; RBM-010 for the treatment of osteoarthritis; and RBM-009 for the treatment of severe asthma, as well as RBM-101, which is in discovery stage for the affinity purification of human IgG and Fc-fusion proteins.
The company was incorporated in 2003 and is headquartered in Minato, Japan.
| Country | Japan |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Yoshikazu Nakamura |
Contact Details
Address: Shirokanedai Usui Building Minato, 108-0071 Japan | |
| Phone | 81 3 3440 3303 |
| Website | ribomic.com |
Stock Details
| Ticker Symbol | 4591 |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3974850004 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Yoshikazu Nakamura | Chief Executive Officer |